← All companies

MRVI

Maravai LifeSciences Holdings, Inc.

MRVI Nasdaq Pharmaceutical Preparations EDGAR ↗

$6.43

+0.01 +0.16%

Key statistics

from XBRL data in SEC filings

Market cap

$942M

Revenue (TTM)

$205M

Net income (TTM)

-$105M

EPS (TTM)

$-0.71

P/E ratio

—

Dividend yield

—

Free cash flow

-$70.7M

Cash

$166M

Total assets

$713M

Gross margin

16.6%

52-week range

$1.99 – $7.44

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement; Terminated a material agreement; Took on a direct financial obligation; Regulation FD disclosure Jun 3, 2026 8-K Shareholder vote results May 29, 2026 10-Q Quarter ended 2026-03-31 May 8, 2026 8-K Results of operations (earnings release) May 7, 2026 10-K Fiscal year ended 2025-12-31 Feb 26, 2026 8-K Results of operations (earnings release) Feb 25, 2026 10-Q Quarter ended 2025-09-30 Nov 7, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Director or officer change Oct 27, 2025 10-Q Quarter ended 2025-06-30 Aug 11, 2025 8-K Results of operations (earnings release); Exit or disposal costs; Director or officer change Aug 11, 2025 8-K Changed accountants Jul 18, 2025 8-K Director or officer change; Regulation FD disclosure Jun 25, 2025 8-K Director or officer change; Regulation FD disclosure Jun 9, 2025 8-K Shareholder vote results May 28, 2025 10-Q Quarter ended 2025-03-31 May 12, 2025 8-K Results of operations (earnings release) May 12, 2025 8-K Regulation FD disclosure Mar 20, 2025 10-K Fiscal year ended 2024-12-31 Mar 18, 2025 8-K Results of operations (earnings release); Previously issued financials not reliable Mar 18, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Feb 25, 2025 8-K Results of operations (earnings release); Director or officer change Jan 8, 2025 8-K Other events Dec 18, 2024 8-K Director or officer change; Regulation FD disclosure Dec 5, 2024 10-Q Quarter ended 2024-09-30 Nov 12, 2024 8-K Results of operations (earnings release) Nov 7, 2024 8-K Entered a material agreement Sep 12, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release) Aug 7, 2024 8-K Director or officer change; Regulation FD disclosure Jul 29, 2024 8-K Director or officer change Jun 12, 2024 8-K Shareholder vote results May 28, 2024 10-Q Quarter ended 2024-03-31 May 9, 2024 8-K Results of operations (earnings release) May 8, 2024 10-K Fiscal year ended 2023-12-31 Feb 29, 2024 8-K Results of operations (earnings release) Feb 22, 2024 10-Q Quarter ended 2023-09-30 Nov 8, 2023 8-K Results of operations (earnings release) Nov 7, 2023 10-Q Quarter ended 2023-06-30 Aug 8, 2023 8-K Results of operations (earnings release) Aug 7, 2023